BALKAN MEDICAL JOURNAL, cilt.31, sa.1, ss.43-49, 2014 (SCI-Expanded)
Background: Anti-vascular endothelial growth factor (Anti-VEGF) agents are a promising approach to increase the efficacy of treatment for treatment-resistant prostate cancer.